Ionis adds former Alexion CEO Ludwig Hantson to board
Share
Listen to the news
Ionis adds former Alexion CEO Ludwig Hantson to board
  • Ionis Pharmaceuticals named former Alexion CEO Ludwig Hantson to its board, effective immediately.
  • Hantson led Alexion from 2017 to 2021 through its sale to AstraZeneca.
  • He previously ran Baxter Bioscience, led the Baxalta spin-off as CEO, held senior roles at Novartis, spent 13 years at Johnson & Johnson.
  • Ionis also added Peter Reikes to the board.
  • Directors Joseph Wender, Lynne Parshall retired.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-024407), on June 08, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending